- Published on
Emergency And Acute Medicine – Cystic Fibrosis
Foundational Overview
Cystic fibrosis is caused by a defect in the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR functions as an ATP-regulated chloride channel that modulates chloride and sodium transport across epithelial cell surfaces. Dysfunction leads to abnormal electrolyte movement in exocrine glands and secretory epithelia. The result is thick, viscous secretions, impaired mucociliary clearance, recurrent pulmonary infections, and progressive obstructive lung disease. Exocrine pancreatic insufficiency causes malabsorption, while chronic sinus disease is common.
Cystic fibrosis occurs in approximately 1 in 3,600 live births in the White population, 1 in 29,000 in African American individuals, and 1 in 6,500 in Hispanic individuals. About 30% of cases are detected through newborn screening, and 75% are diagnosed within the first two years of life. Approximately 30,000 children and young adults in the United States live with cystic fibrosis. Median life expectancy in the U.S. is about 40 years, with 40% of patients older than 18 years. Roughly 10 million Americans are asymptomatic carriers. Sixteen percent of lung transplants in the U.S. are performed for cystic fibrosis–related lung disease.
Predisposing Factors
Cystic fibrosis is an autosomal recessive genetic disorder involving the CFTR gene on the long arm of chromosome 7. Numerous mutations exist, resulting in variable phenotypes. Classic disease is most commonly associated with homozygous ΔF508 mutations. Cystic fibrosis remains the most common lethal genetic disease in the United States.
Infectious Contributors And Pathogenesis
Patients are predisposed to chronic and recurrent pulmonary infections, often involving multidrug-resistant organisms. Common pathogens include methicillin-sensitive and methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa (with prevalence increasing with age and chronic infection in more than 70% of adults), Haemophilus influenzae, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans.
Burkholderia cepacia occurs in approximately 3% of patients and is associated with rapid clinical deterioration. Nontuberculous mycobacteria, including Mycobacterium avium complex and Mycobacterium abscessus, and fungal pathogens such as Aspergillus are also encountered.
Clinical Manifestations
General findings include failure to thrive, recurrent respiratory infections, anasarca in infancy, and a characteristic salty taste of the skin.
Head and neck involvement includes nasal polyps, severe headaches from sinusitis, and recurrent otitis media.
Pulmonary features include persistent cough that progresses from dry to productive, recurrent bronchiolitis or pneumonitis in the first year of life, wheezing, hemoptysis, pneumonia, chronic bronchitis, bronchiectasis, respiratory distress, pneumothorax, and pneumomediastinum. Pulmonary complications are the most common cause of hospitalization.
Cardiac complications include congestive heart failure, cor pulmonale, and pulmonary hypertension.
Gastrointestinal manifestations include abdominal pain, meconium ileus, distal intestinal obstructive syndrome (DIOS, also called meconium ileus equivalent), gastroesophageal reflux, cholelithiasis, pancreatitis, pancreatic insufficiency, ileocecal intussusception, foul-smelling fatty stools, jaundice or cirrhosis, rectal prolapse, hematemesis, and small-intestinal bacterial overgrowth.
Musculoskeletal and systemic findings include bone pain, edema or joint effusions, decreased cortical bone thickness, and recurrent venous thrombosis. Cardiorespiratory failure is the leading cause of death.
Essential Diagnostic Evaluation
Initial confirmation relies on sweat chloride testing. DNA analysis is indicated if sweat testing is equivocal. Nasal potential difference testing is reserved for cases where DNA analysis is inconclusive.
Diagnostic Studies And Interpretation
The sweat chloride test is diagnostic when chloride concentration exceeds 60 mEq/L in the presence of classic symptoms. Stool studies may demonstrate decreased elastase, trypsin, or chymotrypsin, and increased fat on 72-hour fecal fat testing. Immunoreactive trypsin (IRT) screening identifies increased risk but may yield false positives or negatives.
DNA analysis detects approximately 90% of cystic fibrosis chromosomes and is positive when two abnormal CFTR genes are present. Genotyping alone cannot establish the diagnosis, as more than 1,300 CFTR mutations exist and modifying mutations may attenuate disease severity.
Laboratory evaluation may reveal thrombocytopenia, hyponatremic hypochloremic metabolic alkalosis, hyperglycemia or new-onset diabetes in adolescents and adults (with ketoacidosis being rare), and abnormal liver function tests or prolonged prothrombin time in the setting of liver disease or bleeding. Arterial blood gases may show hypoxemia and metabolic alkalosis. Sputum cultures often reveal chronic pseudomonal colonization.
Specialized studies include nasal potential difference testing, which is complex and time-consuming, and semen analysis demonstrating azoospermia in affected males.
Imaging findings on chest radiography include hyperaeration, peribronchial thickening, atelectasis, hilar lymphadenopathy, pneumothorax, pneumomediastinum, bronchiectasis, and blebs. Chest CT better defines bronchiectasis and bleb disease. Abdominal imaging is indicated for pain, vomiting, or distention to evaluate for DIOS or intussusception. Barium enema is used when intussusception is suspected. Routine sinus radiographs are of limited value, as they are almost always abnormal; CT imaging is required for operative planning.
Bronchoalveolar lavage may demonstrate neutrophilic inflammation but is unnecessary when pulmonary disease is clinically evident.
Conditions To Exclude
Respiratory alternatives include asthma, recurrent pneumonia, bronchiectasis from other causes, pertussis, immunodeficiency, foreign body aspiration, alpha-1 antitrypsin deficiency, and ciliary dyskinesia.
Gastrointestinal mimics include chronic diarrhea, gastroenteritis, and milk allergy.
Other causes of elevated sweat electrolytes include fucosidosis, glycogen storage disease type I, mucopolysaccharidoses, hypothyroidism, vasopressin-resistant diabetes insipidus, adrenal insufficiency, familial cholestasis or hypoparathyroidism, malnutrition, ectodermal dysplasia, atopic dermatitis, and prostaglandin E1 infusion.
Emergency And Acute Care Management
Prehospital considerations include transcutaneous pacing for unstable type II second-degree or third-degree heart block. Atropine should be avoided in type II second-degree block due to risk of progression to complete heart block.
Emergency department priorities focus on stabilization of airway, breathing, and circulation, with correction of fluid, electrolyte, glucose, and respiratory abnormalities. Bronchodilators and steroids are used for wheezing. Small pneumothoraces under 5–10% may be observed, while larger ones require thoracostomy. Early consultation with the patient’s cystic fibrosis specialist is essential.
Right-sided heart failure is treated with diuretics. Hemoptysis requires evaluation of coagulation status and transfusion as indicated. Ventilatory support may be necessary in severe respiratory failure.
DIOS often requires surgical intervention. Hematemesis is managed with packed red blood cells, correction of coagulopathy, and early endoscopic consultation. Intussusception is treated with air or barium enema, with surgery if unsuccessful. Rectal prolapse is manually reduced, with surgical consultation as needed.
Respiratory care includes aggressive pulmonary toilet, chest physiotherapy, mucus-thinning inhaled agents, and antibiotics tailored to culture and sensitivity results. Treatment regimens vary based on organism profile, including coverage for MSSA, MRSA, Pseudomonas aeruginosa, Burkholderia cepacia, and Haemophilus influenzae. Ciprofloxacin may replace aminoglycosides when organisms are sensitive.
Disease-specific therapies include CFTR modulators such as ivacaftor to improve protein function, nebulized hypertonic saline to restore airway surface liquid, and dornase alfa to reduce mucus viscosity. Adjunctive strategies include high-dose ibuprofen for anti-inflammatory effects, inhaled antibiotics, nutritional optimization, exercise programs, and consideration of lung transplantation in advanced disease.
Pharmacologic Therapy
Antibiotic regimens include aminoglycosides, antipseudomonal penicillins, cephalosporins, carbapenems, vancomycin, and trimethoprim–sulfamethoxazole, dosed carefully due to altered pharmacokinetics in undernourished patients. Close monitoring of drug levels, particularly with aminoglycosides, is essential.
Disposition And Follow-Up
Hospital admission is required for pulmonary exacerbations with significant decline from baseline, hypoxemia, resistant organisms, or failure of outpatient therapy, as well as pneumothorax, hemoptysis, hematemesis, intussusception, unexplained abdominal pain, bowel obstruction, or hyperglycemia.
Discharge requires close follow-up to review culture sensitivities and adjust therapy. Patients should avoid excessive heat exposure and may require oral salt supplementation during periods of heavy sweating.
Care Coordination And Long-Term Planning
All patients should be followed by a specialized cystic fibrosis pulmonary center. Acute exacerbations warrant early consultation. Long-term care requires a multidisciplinary team approach incorporating airway clearance, antibiotics, nutritional support, pancreatic enzyme replacement, and exercise programs.
Key Clinical Insights And Common Pitfalls
In cystic fibrosis patients with acute respiratory distress, pneumothorax must always be considered and promptly evaluated with chest imaging. In those presenting with abdominal pain or vomiting, distal intestinal obstructive syndrome and intussusception should remain high on the differential.
Foundational Overview
Cystic fibrosis is caused by a defect in the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR functions as an ATP-regulated chloride channel that modulates chloride and sodium transport across epithelial cell surfaces. Dysfunction leads to abnormal electrolyte movement in exocrine glands and secretory epithelia. The result is thick, viscous secretions, impaired mucociliary clearance, recurrent pulmonary infections, and progressive obstructive lung disease. Exocrine pancreatic insufficiency causes malabsorption, while chronic sinus disease is common.
Cystic fibrosis occurs in approximately 1 in 3,600 live births in the White population, 1 in 29,000 in African American individuals, and 1 in 6,500 in Hispanic individuals. About 30% of cases are detected through newborn screening, and 75% are diagnosed within the first two years of life. Approximately 30,000 children and young adults in the United States live with cystic fibrosis. Median life expectancy in the U.S. is about 40 years, with 40% of patients older than 18 years. Roughly 10 million Americans are asymptomatic carriers. Sixteen percent of lung transplants in the U.S. are performed for cystic fibrosis–related lung disease.
Predisposing Factors
Cystic fibrosis is an autosomal recessive genetic disorder involving the CFTR gene on the long arm of chromosome 7. Numerous mutations exist, resulting in variable phenotypes. Classic disease is most commonly associated with homozygous ΔF508 mutations. Cystic fibrosis remains the most common lethal genetic disease in the United States.
Infectious Contributors And Pathogenesis
Patients are predisposed to chronic and recurrent pulmonary infections, often involving multidrug-resistant organisms. Common pathogens include methicillin-sensitive and methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa (with prevalence increasing with age and chronic infection in more than 70% of adults), Haemophilus influenzae, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans.
Burkholderia cepacia occurs in approximately 3% of patients and is associated with rapid clinical deterioration. Nontuberculous mycobacteria, including Mycobacterium avium complex and Mycobacterium abscessus, and fungal pathogens such as Aspergillus are also encountered.
Clinical Manifestations
General findings include failure to thrive, recurrent respiratory infections, anasarca in infancy, and a characteristic salty taste of the skin.
Head and neck involvement includes nasal polyps, severe headaches from sinusitis, and recurrent otitis media.
Pulmonary features include persistent cough that progresses from dry to productive, recurrent bronchiolitis or pneumonitis in the first year of life, wheezing, hemoptysis, pneumonia, chronic bronchitis, bronchiectasis, respiratory distress, pneumothorax, and pneumomediastinum. Pulmonary complications are the most common cause of hospitalization.
Cardiac complications include congestive heart failure, cor pulmonale, and pulmonary hypertension.
Gastrointestinal manifestations include abdominal pain, meconium ileus, distal intestinal obstructive syndrome (DIOS, also called meconium ileus equivalent), gastroesophageal reflux, cholelithiasis, pancreatitis, pancreatic insufficiency, ileocecal intussusception, foul-smelling fatty stools, jaundice or cirrhosis, rectal prolapse, hematemesis, and small-intestinal bacterial overgrowth.
Musculoskeletal and systemic findings include bone pain, edema or joint effusions, decreased cortical bone thickness, and recurrent venous thrombosis. Cardiorespiratory failure is the leading cause of death.
Essential Diagnostic Evaluation
Initial confirmation relies on sweat chloride testing. DNA analysis is indicated if sweat testing is equivocal. Nasal potential difference testing is reserved for cases where DNA analysis is inconclusive.
Diagnostic Studies And Interpretation
The sweat chloride test is diagnostic when chloride concentration exceeds 60 mEq/L in the presence of classic symptoms. Stool studies may demonstrate decreased elastase, trypsin, or chymotrypsin, and increased fat on 72-hour fecal fat testing. Immunoreactive trypsin (IRT) screening identifies increased risk but may yield false positives or negatives.
DNA analysis detects approximately 90% of cystic fibrosis chromosomes and is positive when two abnormal CFTR genes are present. Genotyping alone cannot establish the diagnosis, as more than 1,300 CFTR mutations exist and modifying mutations may attenuate disease severity.
Laboratory evaluation may reveal thrombocytopenia, hyponatremic hypochloremic metabolic alkalosis, hyperglycemia or new-onset diabetes in adolescents and adults (with ketoacidosis being rare), and abnormal liver function tests or prolonged prothrombin time in the setting of liver disease or bleeding. Arterial blood gases may show hypoxemia and metabolic alkalosis. Sputum cultures often reveal chronic pseudomonal colonization.
Specialized studies include nasal potential difference testing, which is complex and time-consuming, and semen analysis demonstrating azoospermia in affected males.
Imaging findings on chest radiography include hyperaeration, peribronchial thickening, atelectasis, hilar lymphadenopathy, pneumothorax, pneumomediastinum, bronchiectasis, and blebs. Chest CT better defines bronchiectasis and bleb disease. Abdominal imaging is indicated for pain, vomiting, or distention to evaluate for DIOS or intussusception. Barium enema is used when intussusception is suspected. Routine sinus radiographs are of limited value, as they are almost always abnormal; CT imaging is required for operative planning.
Bronchoalveolar lavage may demonstrate neutrophilic inflammation but is unnecessary when pulmonary disease is clinically evident.
Conditions To Exclude
Respiratory alternatives include asthma, recurrent pneumonia, bronchiectasis from other causes, pertussis, immunodeficiency, foreign body aspiration, alpha-1 antitrypsin deficiency, and ciliary dyskinesia.
Gastrointestinal mimics include chronic diarrhea, gastroenteritis, and milk allergy.
Other causes of elevated sweat electrolytes include fucosidosis, glycogen storage disease type I, mucopolysaccharidoses, hypothyroidism, vasopressin-resistant diabetes insipidus, adrenal insufficiency, familial cholestasis or hypoparathyroidism, malnutrition, ectodermal dysplasia, atopic dermatitis, and prostaglandin E1 infusion.
Emergency And Acute Care Management
Prehospital considerations include transcutaneous pacing for unstable type II second-degree or third-degree heart block. Atropine should be avoided in type II second-degree block due to risk of progression to complete heart block.
Emergency department priorities focus on stabilization of airway, breathing, and circulation, with correction of fluid, electrolyte, glucose, and respiratory abnormalities. Bronchodilators and steroids are used for wheezing. Small pneumothoraces under 5–10% may be observed, while larger ones require thoracostomy. Early consultation with the patient’s cystic fibrosis specialist is essential.
Right-sided heart failure is treated with diuretics. Hemoptysis requires evaluation of coagulation status and transfusion as indicated. Ventilatory support may be necessary in severe respiratory failure.
DIOS often requires surgical intervention. Hematemesis is managed with packed red blood cells, correction of coagulopathy, and early endoscopic consultation. Intussusception is treated with air or barium enema, with surgery if unsuccessful. Rectal prolapse is manually reduced, with surgical consultation as needed.
Respiratory care includes aggressive pulmonary toilet, chest physiotherapy, mucus-thinning inhaled agents, and antibiotics tailored to culture and sensitivity results. Treatment regimens vary based on organism profile, including coverage for MSSA, MRSA, Pseudomonas aeruginosa, Burkholderia cepacia, and Haemophilus influenzae. Ciprofloxacin may replace aminoglycosides when organisms are sensitive.
Disease-specific therapies include CFTR modulators such as ivacaftor to improve protein function, nebulized hypertonic saline to restore airway surface liquid, and dornase alfa to reduce mucus viscosity. Adjunctive strategies include high-dose ibuprofen for anti-inflammatory effects, inhaled antibiotics, nutritional optimization, exercise programs, and consideration of lung transplantation in advanced disease.
Pharmacologic Therapy
Antibiotic regimens include aminoglycosides, antipseudomonal penicillins, cephalosporins, carbapenems, vancomycin, and trimethoprim–sulfamethoxazole, dosed carefully due to altered pharmacokinetics in undernourished patients. Close monitoring of drug levels, particularly with aminoglycosides, is essential.
Disposition And Follow-Up
Hospital admission is required for pulmonary exacerbations with significant decline from baseline, hypoxemia, resistant organisms, or failure of outpatient therapy, as well as pneumothorax, hemoptysis, hematemesis, intussusception, unexplained abdominal pain, bowel obstruction, or hyperglycemia.
Discharge requires close follow-up to review culture sensitivities and adjust therapy. Patients should avoid excessive heat exposure and may require oral salt supplementation during periods of heavy sweating.
Care Coordination And Long-Term Planning
All patients should be followed by a specialized cystic fibrosis pulmonary center. Acute exacerbations warrant early consultation. Long-term care requires a multidisciplinary team approach incorporating airway clearance, antibiotics, nutritional support, pancreatic enzyme replacement, and exercise programs.
Key Clinical Insights And Common Pitfalls
In cystic fibrosis patients with acute respiratory distress, pneumothorax must always be considered and promptly evaluated with chest imaging. In those presenting with abdominal pain or vomiting, distal intestinal obstructive syndrome and intussusception should remain high on the differential.
0 Comments
